Incorrect use of Eldisin 5 mg dry vial (Vindesin Sulfate).
The preparation Eldisin 5 mg dry ampoules (active ingredient: vindesine sulfate) has been approved in Austria since March 29, 1984. Vindesine is a cytostatic drug from the group of vinca alkaloids and has proven effective primarily in combination with other oncolytically active preparations as a last-line medication in the treatment of acute lymphoblastic leukemia, malignant lymphoma and non-small cell lung cancer (NSCLC).
Vindesine binds to microtubular proteins and leads to microtubule depolymerization, preventing mitotic spindle formation and causing arrest of mitosis in metaphase.
Due to poor absorption from the gastrointestinal tract, vindesine is administered intravenously as a bolus injection over one to three minutes.
Eldisine is only injected intravenously and must not be administered intrathecally, as this mode of application can also be lethal. Paravenous injection should also be avoided due to serious side effects.
Situation in Austria
The following medicinal products are approved in Austria:
- Eldisin 5 mg dry vial.
BASG Recommendations.
Recommendations for users:
- Appropriate measures must be taken during administration to ensure that the product is used in accordance with the technical and instructions for use.
